Recombinant Bovine Somatotropin vs Advantame: which is worse?
Quick answer: Recombinant Bovine Somatotropin carries the heavier risk profile. Recombinant Bovine Somatotropin is — in the EU and — in the US; Advantame is — in the EU and — in the US.
| Property | Recombinant Bovine Somatotropin | Advantame |
|---|---|---|
| EU status | — | — |
| US status | — | — |
| Risk level | — | — |
| Banned in | European Union, Canada, Japan, Australia, New Zealand | — |
| Restricted in | — | European Union (ADI 5 mg/kg body weight) |
| Category | additive | additive |
| Where it hides | — | — |
What is Recombinant Bovine Somatotropin?
Recombinant bovine somatotropin (rBST) is the synthetic version of bovine growth hormone (BST), naturally produced by the pituitary gland in cattle. The recombinant version is produced using genetically engineered bacteria and is injected into dairy cows to increase milk production by 10-15%. Brand name: Posilac.
What is Advantame?
Advantame is the newest FDA-approved synthetic sweetener, approved in 2014. Like neotame, it is a structural derivative of aspartame but with a vanillin-derived substituent. It is approximately 20,000 times sweeter than sucrose — the most potent sweetener currently approved for food use in the US.
Documented risks
Recombinant Bovine Somatotropin: See recombinant-bovine-growth-hormone-rbgh for full detail. Key concerns: rBST elevates IGF-1 in milk; elevated blood IGF-1 is associated with breast, prostate, and colorectal cancer risk in epidemiological studies. Animal welfare: increased mastitis (up to 25-50% higher rates), lameness, and antibiotic use. The Codex Alimentarius Commission declined to endorse rBST safety MRLs in a historic 33-29 vote. Health Canada rejected rBST approval in 1999 after finding it caused significant animal health problems requiring increased antibiotic use.
Advantame: Advantame is the newest approved high-intensity sweetener with the least post-approval safety data. The FDA approval was based on extensive pre-market animal studies showing no significant toxicity, carcinogenicity, reproductive toxicity, or neurotoxicity at relevant doses. EFSA approved it for EU use in 2014, finding no safety concerns based on the submitted data. Like other synthetic sweeteners, advantame has not been studied for long-term effects in large human populations post-approval. The same gut microbiome and glucose tolerance concerns raised for other sweeteners (aspartame, sucralose, acesulfame K) have not been specifically studied for advantame, though the class-wide concerns are relevant. Given its 2014 approval date, independent long-term safety studies are still limited.
Scan a barcode and we'll flag both Recombinant Bovine Somatotropin and Advantame (plus 200+ other ingredients banned overseas).
Scan free →